Zhitong Finance App News, Zhixiang Jintai (688443.SH) issued an announcement. Recently, the company received a “Notice of Acceptance” from the State Drug Administration regarding the application for registration and marketing of “GR1803 injection” drugs. The indications for this application to be approved for marketing are that this product is suitable for adult patients with recurrent or refractory multiple myeloma who have received at least three lines of treatment in the past (including a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody).

Zhitongcaijing · 4d ago
Zhitong Finance App News, Zhixiang Jintai (688443.SH) issued an announcement. Recently, the company received a “Notice of Acceptance” from the State Drug Administration regarding the application for registration and marketing of “GR1803 injection” drugs. The indications for this application to be approved for marketing are that this product is suitable for adult patients with recurrent or refractory multiple myeloma who have received at least three lines of treatment in the past (including a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody).